EU Parliament Intervention Threatens Right to Fair Trial in Berta Cáceres Case in Honduras, Says Lawyer Robert Amsterdam
LONDON, Nov. 27, 2018 (GLOBE NEWSWIRE) -- On Thursday 29 November 2018 a Honduran criminal court is expected to issue a ruling against eight individuals accused of involvement in the 2016 murder of the activist Berta Cáceres.
The case has attracted large international interest, including a letter last Thursday (22 November 2018) from 32 MEPs from the European Union (EU) Parliament, alongside Federica Mogherini the High Representative for the EU, calling upon the Honduran authorities to guarantee a fair trial for Berta Cáceres.
However, worries are felt in some quarters that two of the accused, including DESA executives Sergio Rodriguez Orellana and Roberto David Castillo (the latter of whom is being tried separately), who have been held in pretrial detention for an extended period, are political prisoners, victims of the international pressures felt by the Honduran authorities.
Robert Amsterdam, the lead lawyer for DESA in the case said:
“The European Parliament’s intervention into the Berta Cáceres trial at this point could not be more dangerous. The continued pressure applied by the EU risks increasing the likelihood of false prosecutions rather than delivering the fair trial they call for.
“Applying undue pressure on the Honduran authorities to prosecute those currently charged, before the full evidence has been heard, is a blatant disregard to their human rights and safeguarding of the rule of law.
“Justice for the relatives and friends of Ms. Caceres will only be delivered if those accused of her murder receive a trial that is fair and free from interference and coercion.”
Mr. Amsterdam said that problems with the legal process have been suffered by both sides and calls to ensure a fair trial have been made by both the victims and the defendants.
“Currently, the trial cannot deliver a just outcome. Central to our concerns is that COPINH, the organization of which Ms. Caceres was a member, is interfering in the judicial process with a reckless pressure campaign, spreading misinformation about the defendants and DESA to further a political agenda.
“I call upon the European Parliament to ensure the environment around this case does not become more fervent and vitriolic, and we ensure the rights to a presumption of innocence and a fair trial are upheld, for all Hondurans.”
Amsterdam concluded by saying he’s written to the MEPs to respond to the letter dated 16 November 2018.
The letter follows the publication of the white paper “War on Development” released by Amsterdam & Partners LLP on 15 November, 2018. The report accuses activists of spreading false information, attacking the right to a fair trial, and blocking economic development in Honduras.
The Paper is available to download in English and Spanish http://casocaceres.com.
More information about Amsterdam & Partners LLP is available at https://amsterdamandpartners.com.
Amsterdam & Partners LLP
1054 31st Street, NW
Washington, DC 20007
+44 (0) 20 7406 7456
+44 (0) 7384 253 436
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Gainsight Unveils the Customer Cloud, the Future of Customer Success Technology23.5.2019 19:30:00 CEST | Pressemelding
New Products Announced at Pulse 2019 to Drive Customer Success Across the Enterprise SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- Today, Gainsight® launched the Customer Cloud —a first-of-its-kind solution for subscription businesses looking to adopt a customer-centric philosophy that enables them to retain customers while also driving company growth post-sale. According to the 2018 Subscription Economy Index report, subscription companies are growing five times faster than S&P and retail sales. The Gainsight Customer Cloud caters to these businesses by combining the company’s Customer Success and Product Experience products with three new product innovations to offer a powerful set of solutions for businesses to optimize their subscription strategies through technology. “With the maturity of cloud technology and the subscription economy, customer expectations have drastically changed. Companies are struggling to leverage existing tools to satisfy the increasing demands of their cus
Lowered Return Expectations Among Several Trends Pointing to a Shift in Private Markets Due Diligence says New eVestment Survey23.5.2019 15:30:00 CEST | Pressemelding
ATLANTA, May 23, 2019 (GLOBE NEWSWIRE) -- Private markets funds have continued to rake in new commitments from institutional investors eager to diversify their portfolios and capture the returns private markets investments can offer. However, investors are now tempering their private markets return expectations. Coupled with other industry trends, this will have implications for private markets fundraising and due diligence according to a new eVestment report, produced in association with parent company Nasdaq. The 2019 eVestment Private Markets Due Diligence Survey of institutional investors, consultants and private markets fund managers finds that 52% of investors expect returns in the space to decline in the future (page 16). Only 12% of investors expected private equity returns to increase, with the balance – 36% – expecting returns to stay about the same. Forty-seven percent of investors surveyed expect to see lower returns in venture capital vs. just 16% of investors who expect r
Collibra Announces 2019 Excellence Awards Winners23.5.2019 15:00:00 CEST | Pressemelding
American Express, Deloitte, and Lloyds Banking Group recognized as leaders in harnessing data to drive digital transformation NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Collibra, the leader in enterprise data governance and catalog software, today announced the winners of the 2019 Collibra Excellence Awards. Presented at the annual Data Citizens conference in New York, the awards honor teams and individuals driving innovative data strategy by collaborating with Collibra. “In today’s market, organizations that are able to maximize data have the power to transform entire industries,” said Felix Van de Maele, co-founder and CEO of Collibra. “We’re proud to honor the recipients of the Collibra Excellence Awards, a cutting-edge group at the forefront of data-driven innovation.” The 2019 Collibra Excellence Award Winners: American Express — Distinguished Data Program of the Year American Express was recognized for its data governance transformation, which began as a compliance initiative and
XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa23.5.2019 14:20:00 CEST | Pressemelding
AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The study will further evaluate efficacy of bermekimab in HS and guide dosing strategies for the anticipated Phase 3 registration study. The Company expects the first patient to be enrolled during the third quarter of 2019. The Phase 2b study follows two previous successful clinical studies of bermekimab to treat HS. XBiotech recently evaluated bermekimab in a phase 2 study involving two groups of patients with HS: those who had no prior treatment with biologics; and those who had failed the only approved biological therapy to treat HS. The study, whi
LGC CAPITAL Announces Results of Annual Meeting, Appointment of New Chairman and Approval of Name Change to Elixxer Ltd.23.5.2019 14:00:00 CEST | Pressemelding
MONTRÉAL, May 23, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held yesterday in Montreal, Quebec. At the Meeting, all five of the nominees listed in the Corporation’s management information circular dated April 17, 2019 were elected as directors, all with a vote of more than 92% of the shares voted in their favour. Accordingly, the directors of LGC for the ensuing year are Mohammed Ghafari, Mazen Haddad, Rafi Hazan, David Lenigas and Ferras Zalt. At the Meeting, shareholders adopted a special resolution approving a change in the name of the Corporation to “Elixxer Ltd.” or such other name as the Corporation’s directors may determine. The special resolution was supported by 98.94% of the votes cast at the Meeting. The Corporation intends to proceed with the name change as expeditiously as possible. Shareholders also adopted: a special
Merus Announces 2019 Annual General Meeting of Shareholders23.5.2019 14:00:00 CEST | Pressemelding
UTRECHT, The Netherlands, May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General Meeting of Shareholders will be held on June 12, 2019 at 1:00 pm (CEST) at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus’ website (www.merus.nl) under “Financial Information”. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clin